Just Approved & Launched

•   The U.S. Food and Drug Administration (FDA) has approved the first once-daily Arcapta™ Neohaler™ (indacaterol inhalation powder) 75 mcg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. Manufactured by Novartis Pharmaceuticals Corporation, Arcapta is not indicated for acute deteriorations of COPD or to treat asthma.

•   The FDA has approved XARELTO® (rivaroxaban tablets), a novel, once-daily, oral anti-coagulant for the prevention of deep vein thrombosis, which may lead to pulmonary embolism in people undergoing knee or hip replacement surgery. To date, the drug, which is manufactured by Bayer HealthCare, has been successfully launched in 80 countries. Janssen Pharmaceuticals, Inc., holds the marketing rights for XARELTO® in the United States. 

The image on the right does not represent the product described in this column.